Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 2,517 | $43.63 | $109,816.71 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 22:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,457 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001567619-19-002397 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,914 Underlying: ResMed Common Stock · 4,457 shares Expires 2020-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 22:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,457 | $93.50 | $416,729.50 |
DisclosureSEC source: 0001567619-19-002397 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,002 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 22:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,457 | $51.25 | $228,421.25 |
DisclosureSEC source: 0001567619-19-002397 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F1 · balance_after: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 17:37 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001567619-19-002214 · doc1.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,038 Underlying: ResMed Commmon Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 17:37 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $95.09 | $76,072.00 |
DisclosureSEC source: 0001567619-19-002214 · doc1.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,089 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 17:37 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $95.09 | $76,072.00 |
DisclosureSEC source: 0001567619-19-002214 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,889 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 17:37 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001567619-19-002214 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 00:12 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $92.30 | $276,900.00 |
DisclosureSEC source: 0001567619-19-002059 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:25 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,307 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-19-001242 · doc1.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,758 Underlying: ResMed Commmon Stock · 3,307 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:25 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 881 | $114.18 | $100,592.58 |
DisclosureSEC source: 0001567619-19-001242 · doc1.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 155,332 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:25 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,307 | $114.18 | $377,593.26 |
DisclosureSEC source: 0001567619-19-001242 · doc1.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,421 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:25 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,307 | $43.63 | $144,284.41 |
DisclosureSEC source: 0001567619-19-001242 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:18 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $114.18 | $228,360.00 |
DisclosureSEC source: 0001567619-19-001237 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F1 · shares: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:06 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-19-001236 · doc1.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,517 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:06 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 6,651 | $113.75 | $756,551.25 |
DisclosureSEC source: 0001567619-19-001236 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $113.38 to $114.07. The price reported above reflects the weighted average sale price. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:06 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001567619-19-001236 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 20:48 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,457 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001567619-19-000493 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,371 Underlying: ResMed Common Stock · 4,457 shares Expires 2020-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 20:48 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,457 | $110.82 | $493,924.74 |
DisclosureSEC source: 0001567619-19-000493 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,002 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 20:48 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,457 | $51.25 | $228,421.25 |
DisclosureSEC source: 0001567619-19-000493 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F1 · balance_after: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:04 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001567619-19-000256 · doc1.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,838 Underlying: ResMed Commmon Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:04 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 800 | $112.13 | $89,704.00 |
DisclosureSEC source: 0001567619-19-000256 · doc1.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,889 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:04 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 800 | $112.13 | $89,704.00 |
DisclosureSEC source: 0001567619-19-000256 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,689 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:04 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001567619-19-000256 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 22:56 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $112.50 | $337,500.00 |
DisclosureSEC source: 0001567619-19-000132 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 18:43 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 86 | $106.94 | $9,196.84 |
DisclosureSEC source: 0001567619-18-008417 · doc1.xml · nonDerivative · entry 3 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,378 F3 · shares: Disposition to issuer for corrected tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 18:43 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 77 | $106.94 | $8,234.38 |
DisclosureSEC source: 0001567619-18-008417 · doc1.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,464 F2 · shares: Disposition to issuer for corrected tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 18:43 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 67 | $106.94 | $7,164.98 |
DisclosureSEC source: 0001567619-18-008417 · doc1.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,541 F1 · shares: Disposition to issuer for corrected tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 18:37 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 45 | $106.94 | $4,812.30 |
DisclosureSEC source: 0001567619-18-008414 · doc1.xml · nonDerivative · entry 2 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,404 F2 · shares: Disposition to issuer for corrected tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 18:37 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 58 | $106.94 | $6,202.52 |
DisclosureSEC source: 0001567619-18-008414 · doc1.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,449 F1 · shares: Disposition to issuer for corrected tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 00:15 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,307 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-18-008313 · doc1.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,065 Underlying: ResMed Commmon Stock · 3,307 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 00:15 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 886 | $112.56 | $99,728.16 |
DisclosureSEC source: 0001567619-18-008313 · doc1.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 108,336 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 00:15 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,307 | $112.56 | $372,235.92 |
DisclosureSEC source: 0001567619-18-008313 · doc1.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,298 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 00:15 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,307 | $43.63 | $144,284.41 |
DisclosureSEC source: 0001567619-18-008313 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 17, 2018 Filed Dec 20, 2018 18:38 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $112.56 | $225,120.00 |
DisclosureSEC source: 0001567619-18-008415 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F1 · shares: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| December 13, 2018 Filed Dec 13, 2018 23:20 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 13,866 | $115.40 | $1,600,067.07 |
DisclosureSEC source: 0001567619-18-007954 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,301 F1 · kind: Represents a gift of shares to Bank of America, N.A. Successor Trustee of Peter C. Farrell Charitable Remainder Unitrust. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F2 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 17:12 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,455 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001567619-18-007390 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,828 Underlying: ResMed Common Stock · 4,455 shares Expires 2020-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 17:12 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,455 | $112.09 | $499,360.95 |
DisclosureSEC source: 0001567619-18-007390 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,002 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 17:12 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,455 | $51.25 | $228,318.75 |
DisclosureSEC source: 0001567619-18-007390 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 17:11 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 600 | $112.09 | $67,254.00 |
DisclosureSEC source: 0001567619-18-007389 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,689 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 17:09 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $110.50 | $331,500.00 |
DisclosureSEC source: 0001567619-18-007211 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 17:08 UTC |
McHale RichardPresident, RC Business
|
SaleResMed Common Stock | 1,800 | $111.56 | $200,808.00 |
DisclosureSEC source: 0001567619-18-007209 · doc1.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,507 F1 · price: This transaction was executed in multiple trades at prices ranging from $111.55 to $111.57. The price reported above reflects the weighted average sale price. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 17:07 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResmed Stock Option Plan · Derivative | 9,168 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-18-007208 · doc1.xml · derivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 9,168 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually on the grant anniversary. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 17:07 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResMed Common Stock | 9,168 | $43.63 | $399,999.84 |
DisclosureSEC source: 0001567619-18-007208 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2018 Filed Nov 27, 2018 22:45 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 5,893 | $105.52 | $621,829.36 |
DisclosureSEC source: 0001567619-18-007000 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,121 F1 · price: This transaction was executed in multiple trades at prices ranging from $105.30 to $105.80. The price reported above reflects the weighted average sale price. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 23:05 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 57,763 | $104.18 | $6,017,749.34 |
DisclosureSEC source: 0001567619-18-006951 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 23:05 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 103,558 | $104.18 | $10,788,672.44 |
DisclosureSEC source: 0001567619-18-006951 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,045 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on November 21, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 22:55 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 38,465 | $104.18 | $4,007,283.70 |
DisclosureSEC source: 0001567619-18-006943 · doc1.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,298 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 22:55 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 68,958 | $104.18 | $7,184,044.44 |
DisclosureSEC source: 0001567619-18-006943 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,763 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on November 21, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 22:36 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 16,071 | $104.18 | $1,674,276.78 |
DisclosureSEC source: 0001567619-18-006938 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,014 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.